ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Relative Bioavailability of BIBF 1120 Soft Gelatine Capsules Charge 1, BIBF 1120 Soft Gelatine Capsules Charge 2 and BIBF 1120 Drinking Solution in Healthy Male Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02182193
Recruitment Status : Completed
First Posted : July 8, 2014
Last Update Posted : July 18, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
To assess pharmacokinetics and the relative bioavailability of a single dose of BIBF 1120 soft gelatine capsule charge 1 vs. BIBF 1120 soft gelatine capsule charge 2 vs BIBF 1120 drinking solution in healthy male subjects respectively. To establish an in-vitro-in-vivo correlation (IVIVC) for oral soft gelatine capsules with 150 mg BIBF 1120 in healthy male volunteers (if feasible)

Condition or disease Intervention/treatment Phase
Healthy Drug: BIBF 1120 capsules charge 1 Drug: BIBF 1120 capsules charge 2 Drug: BIBF 1120 drinking solution Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Relative Bioavailability of a Single Dose of 150 mg BIBF 1120 Administered as Soft Gelatine Capsules Charge 1 Compared to BIBF 1120 Soft Gelatine Capsules Charge 2 Compared to BIBF 1120 Administered as Drinking Solution Following Oral Administration to Healthy Male Volunteers in an Open, Randomised, Intra-individual, Crossover Comparison Design
Study Start Date : September 2006
Actual Primary Completion Date : November 2006

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BIBF 1120 capsules charge 1 Drug: BIBF 1120 capsules charge 1
Experimental: BIBF 1120 capsules charge 2 Drug: BIBF 1120 capsules charge 2
Active Comparator: BIBF 1120 drinking solution Drug: BIBF 1120 drinking solution



Primary Outcome Measures :
  1. Area under the plasma concentration-time curve of the analyte from zero time (pre-dose) extrapolated to infinity (AUC0-∞) [ Time Frame: 1 h pre dose and up to 48 h after drug administration ]
  2. Individual maximum observed concentrations of the analyte in plasma (Cmax) [ Time Frame: 1 h pre dose and up to 48 h after drug administration ]

Secondary Outcome Measures :
  1. Area under the plasma concentration-time curve of the analyte over the time interval from time zero (pre-dose) to 24 hours (AUC0-24) [ Time Frame: 1 h pre dose and up to 24 h after drug administration ]
  2. time from dosing to the maximum concentration of the analyte in plasma (tmax) [ Time Frame: 1 h pre dose and up to 48 h after drug administration ]
  3. Terminal rate constant in plasma (λz) [ Time Frame: 1 h pre dose and up to 48 h after drug administration ]
  4. Terminal half-life of the analyte in plasma (t1/2) [ Time Frame: 1 h pre dose and up to 48 h after drug administration ]
  5. Mean residence time of the analyte in the body after oral administration (MRTpo) [ Time Frame: 1 h pre dose and up to 48 h after drug administration ]
  6. Apparent clearance of the analyte in the plasma after extravascular administration (CL/F) [ Time Frame: 1 h pre dose and up to 48 h after drug administration ]
  7. Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F) [ Time Frame: 1 h pre dose and up to 48 h after drug administration ]
  8. Change in vital signs (blood pressure, pulse rate) [ Time Frame: Baseline, up to 24 hours after drug administration ]
  9. Change in routine laboratory values [ Time Frame: pre-dose, up to 48 hours after drug administration ]
  10. Change in ECG [ Time Frame: pre-dose, 4 hours after drug administration, day 32 ]
  11. Occurrence of adverse events [ Time Frame: up to 32 days after drug administration ]
  12. Assessment of tolerability by investigator on a 4 point scale [ Time Frame: 48 hours after drug administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy male subjects as determined by results of screening
  2. Signed written informed consent in accordance with GCP and local legislation
  3. Age ≥21 and ≤55 years
  4. Body Mass Index ≥18.5 kg/m2 and ≤29.9 kg/m2

Exclusion Criteria:

  1. Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
  2. History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders
  3. History of relevant orthostatic hypotension, fainting spells and blackouts
  4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  5. Chronic or relevant acute infections
  6. History of allergy/hypersensitivity (including drug allergy or its excipients) which is deemed relevant to the trial as judged by the investigator
  7. History of any bleeding disorder including prolonged or habitual bleeding, other hematologic disease or cerebral bleeding (e.g. after a car accident) or commotio cerebri
  8. Intake of drugs with a long half-life (> 24 hours) within 1 month prior to administration
  9. Use of any drugs which might influence the results of the trial within 14 days prior to administration or during the trial
  10. Participation in another trial with an investigational drug within 2 months prior to administration or during trial
  11. Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on study days
  12. Alcohol abuse (> 60 g/day)
  13. Drug abuse
  14. Blood donation (more than 150 mL within 4 weeks prior to administration or during the trial)
  15. Excessive physical activities within 5 days prior to administration or during the trial
  16. Any laboratory value outside the reference range that is of clinical relevance
  17. Female gender
  18. Male subjects refuse to minimize the risk of female partners becoming pregnant from the first dosing day until 3 months after the completion of the study. Acceptable methods of contraception for male volunteers include a vasectomy no less than 3 months prior to dosing, barrier contraception or a medically accepted contraceptive method. For female partners of male volunteers, acceptable methods of contraception include intra-uterine device, tubal ligation, hormonal contraceptive since at least two months and diaphragm with spermicide

Additional Information:
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02182193     History of Changes
Other Study ID Numbers: 1199.21
First Posted: July 8, 2014    Key Record Dates
Last Update Posted: July 18, 2014
Last Verified: July 2014

Additional relevant MeSH terms:
Pharmaceutical Solutions
Nintedanib
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action